
Luminex Receives FDA Emergency Use Authorization for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay.
Luminex Receives FDA Emergency Use Authorization for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay.
Quest Diagnostics will now able to efficiently test larger groups of specimen among persons from low-coronavirus risk areas.
Results highlight burden of disease and potential issues associated with contact tracing.
Contracting influenza increased the risk for invasive pneumococcal disease in a study conducted across 3 countries.
Perspective on how the anticoagulant could progress to human trials and potentially, marketing use for coronavirus prevention.
In a small Italian study, a majority of patients who were hospitalized and recovered from the virus, had lingering symptoms and many had a “worsened quality of life.”
Weekly, we identify FDA announcements that pertain to infectious disease care. This week, FDA continued an investigation of undeclared wood alcohol contents in hand sanitizer.
Asymptomatic and presymptomatic cases of COVID-19 create challenges for identifying and combating the spread of the virus in detention facilities.
A discussion with an RPI investigator after promising early findings.
A modeling study from Imperial College shows the COVID-19 pandemic may have significant effect on mortality among other infectious disease patients.
A model including clinical symptom reports, Internet searches, and emergency room data predict influenza hospitalizations better in affluent vs. poorer communities.
West and Central African nations have been developing infrastructure to combat ebola, malaria, malnutrition, and more.
A paper examines how these droplets are transmitted and ways to protect these providers from COVID-19.
A modeling study from Imperial College shows the COVID-19 pandemic may require balancing with other infectious disease priorities.
The burden of COVID-19 is far reaching and a new study into excess mortality sheds light on this saddening topic.
Tens of thousands of patients were prescribed the anti-malarial drugs in the early weeks of the pandemic, a statistic that concerns public health officials.
Heparin may lower the odds of SARS-CoV-2 infection, according to investigators from the Rensselaer Polytechnic Institute.
Rajiv Dhand, MD, discusses the importance of everyone wearing face masks including health care workers seeing patients outside the hospital setting.
New study findings shed light on the positive effects of baloxavir for preventing influenza spread in household settings.
In Mbandaka, an 11th outbreak of Ebola is emerging. This outbreak has renewed questions about what makes the virus such a challenge for Congolese society to reign in.
Following an outbreak of both COVID-19 and H1N1 influenza, Parisian hospital admissions for Kawasaki disease increased.
Skilled nursing facilities are facing an unprecedented crisis as deaths rise amid the COVID-19 pandemic while admissions and patient census decline, a new study shows.
The mRNA-1273 vaccine candidate from Moderna will progress to a phase 3 trial in adults later this summer.
Why it's critical for the future of HIV prevention for programs like the California PrEP-AP to reach younger at-risk persons now.
A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.
In the second segment of the interview, Gilead’s Gelezinuas and SenGupta discuss the areas of unmet HIV therapy needs, cure research, and the benefits of a virtual conference.
A new study finds patients with Clostridium difficile infection are more likely to face a recurrence of the infection if they also have renal impairment. However, bezlotoxumab can reduce that risk.
A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.
How a sexually-transmitted virus is hindered by limited marketing, and how its stigmas compare to those developing around COVID-19.
Pfizer and BioNTech were given approval by the federal agency to expedite their work on investigational vaccines.